Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a buy rating to a hold rating in a research note released on Saturday morning, BidAskClub reports.

ENTA has been the topic of a number of other reports. Wolfe Research assumed coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They set an outperform rating and a $117.00 target price on the stock. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating and set a $99.00 target price on the stock in a research note on Friday, May 10th. Finally, Berenberg Bank upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating and upped their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $111.20.

Shares of NASDAQ:ENTA opened at $82.09 on Friday. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 23.59 and a beta of 1.18. The stock’s 50-day simple moving average is $90.18. Enanta Pharmaceuticals has a 1 year low of $64.08 and a 1 year high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The company had revenue of $39.60 million for the quarter, compared to analyst estimates of $40.92 million. During the same period in the prior year, the firm earned $0.61 earnings per share. The business’s revenue for the quarter was down 10.0% compared to the same quarter last year. On average, equities analysts predict that Enanta Pharmaceuticals will post 1.9 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in ENTA. First Trust Advisors LP raised its position in Enanta Pharmaceuticals by 11.9% in the first quarter. First Trust Advisors LP now owns 25,234 shares of the biotechnology company’s stock worth $2,410,000 after acquiring an additional 2,681 shares in the last quarter. FMR LLC increased its position in shares of Enanta Pharmaceuticals by 19.5% in the first quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock valued at $22,944,000 after buying an additional 39,200 shares in the last quarter. Marshall Wace North America L.P. increased its position in shares of Enanta Pharmaceuticals by 1,128.7% in the first quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock valued at $21,558,000 after buying an additional 207,326 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at $1,433,000. Finally, THB Asset Management purchased a new position in shares of Enanta Pharmaceuticals in the first quarter valued at $341,000. Hedge funds and other institutional investors own 89.49% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: Float

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.